Harpoon Therapeutics raises $45m in new funding round
The financing was co-led by Arix Bioscience and New Leaf Venture Partners. Mark Chin, Investment Manager at Arix, and Ron Hunt, Managing Director at New Leaf, will join
Aspect Biosystems has secured a C$79m($56.6m) investment from the Government of Canada to support a C$280m multi-year project aimed at advancing its pipeline of bioengineered cellular medicines for endocrine and metabolic diseases.